PMID- 29022040
OWN - NLM
STAT- MEDLINE
DCOM- 20181024
LR  - 20181113
IS  - 2737-5935 (Electronic)
IS  - 0037-5675 (Print)
IS  - 0037-5675 (Linking)
VI  - 59
IP  - 5
DP  - 2018 May
TI  - Short-term outcomes of patients with Type 2 diabetes mellitus treated with 
      canagliflozin compared with sitagliptin in a real-world setting.
PG  - 251-256
LID - 10.11622/smedj.2017095 [doi]
AB  - INTRODUCTION: We aimed to evaluate the effectiveness and safety of canagliflozin 
      as compared to sitagliptin in a real-world setting among multiethnic patients 
      with Type 2 diabetes mellitus (T2DM) in Singapore. METHODS: This was a new-user, 
      active-comparator, single-centre retrospective cohort study. Patients aged 18-69 
      years with T2DM and estimated glomerular filtration rate >/= 60 mL/min/1.73 m(2) 
      were eligible for inclusion if they were initiated and maintained on a steady 
      daily dose of canagliflozin 300 mg or sitagliptin 100 mg between 1 May and 31 
      December 2014, and followed up for 24 weeks. RESULTS: In total, 57 patients 
      (canagliflozin 300 mg, n = 22; sitagliptin 100 mg, n = 35) were included. The 
      baseline patient characteristics in the two groups were similar, with overall 
      mean glycated haemoglobin (HbA1c) of 9.4% +/- 1.4%. The use of canagliflozin 300 mg 
      was associated with greater reductions in HbA1c (least squares [LS] mean change 
      -1.6% vs. -0.4%; p < 0.001), body weight (LS mean change -3.0 kg vs. 0.2 kg; p < 
      0.001) and systolic blood pressure (LS mean change: -9.7 mmHg vs. 0.4 mmHg; p < 
      0.001), as compared with sitagliptin 100 mg. About half of the patients on 
      canagliflozin 300 mg reported mild osmotic diuresis-related side effects that did 
      not lead to drug discontinuation. CONCLUSION: Our findings suggest that 
      canagliflozin was more effective than sitagliptin in reducing HbA1c, body weight 
      and systolic blood pressure in patients with T2DM, although its use was 
      associated with an increased incidence of mild osmotic diuresis-related side 
      effects.
CI  - Copyright: (c) Singapore Medical Association.
FAU - Shao, Yan Li
AU  - Shao YL
AD  - Diabetes Centre, Admiralty Medical Centre and Khoo Teck Puat Hospital, Singapore.
FAU - Yee, Kuan Hao
AU  - Yee KH
AD  - National University of Ireland, Ireland.
FAU - Koh, Seow Ken
AU  - Koh SK
AD  - Department of Pharmacy, Khoo Teck Puat Hospital, Singapore.
FAU - Wong, Yip Fong
AU  - Wong YF
AD  - Diabetes Centre, Admiralty Medical Centre and Khoo Teck Puat Hospital, Singapore.
FAU - Yeoh, Lee Ying
AU  - Yeoh LY
AD  - Department of Medicine, Khoo Teck Puat Hospital, Singapore.
FAU - Low, Serena
AU  - Low S
AD  - Clinical Research Unit, Khoo Teck Puat Hospital, Singapore.
FAU - Sum, Chee Fang
AU  - Sum CF
AD  - Diabetes Centre, Admiralty Medical Centre and Khoo Teck Puat Hospital, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20171012
PL  - India
TA  - Singapore Med J
JT  - Singapore medical journal
JID - 0404516
RN  - 0 (Blood Glucose)
RN  - 0 (Hemoglobins)
RN  - 0 (Hypoglycemic Agents)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Blood Glucose/drug effects
MH  - Blood Pressure
MH  - Body Mass Index
MH  - Body Weight
MH  - Canagliflozin/*administration & dosage
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage
MH  - Least-Squares Analysis
MH  - Male
MH  - Middle Aged
MH  - Osmosis
MH  - Retrospective Studies
MH  - Singapore
MH  - Sitagliptin Phosphate/*administration & dosage
MH  - Systole
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC5966634
OTO - NOTNLM
OT  - canagliflozin
OT  - dipeptidyl peptidase-4 inhibitor
OT  - sitagliptin
OT  - sodium glucose co-transporter 2 inhibitor
OT  - type 2 diabetes mellitus
EDAT- 2017/10/13 06:00
MHDA- 2018/10/26 06:00
PMCR- 2018/05/01
CRDT- 2017/10/13 06:00
PHST- 2017/10/13 06:00 [pubmed]
PHST- 2018/10/26 06:00 [medline]
PHST- 2017/10/13 06:00 [entrez]
PHST- 2018/05/01 00:00 [pmc-release]
AID - j59/5/251 [pii]
AID - SMJ-59-251 [pii]
AID - 10.11622/smedj.2017095 [doi]
PST - ppublish
SO  - Singapore Med J. 2018 May;59(5):251-256. doi: 10.11622/smedj.2017095. Epub 2017 
      Oct 12.